Chengdu Olymvax Biopharmaceuticals Inc.’s Net Profit Dropped 48.3% in First Three Quarters of 2022

Chengdu Olymvax Biopharmaceuticals Inc. (成都欧林生物科技股份有限公司) (688319.SH) reported a net profit of 40.2 million yuan in the first three quarters of 2022, down 48.3% year-on-year.

Meanwhile, the company posted 370.8 million yuan in revenue, up 30.2% year-on-year.

At the end of the reporting period, it had 1.4 billion yuan in total assets and 475.5 million yuan in total liabilities, with a liability-to-asset ratio of 34.9%.